Showing 1 - 2 results of 2, query time: 0.05s Refine Results
  1. 1
    A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury.

    A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury. by Pavel I Pilipenko, Anna A Ivanova, Yulia V Kotsiubinskaya, Vera N Grigoryeva, Alexey Y Khrulev, Anatoly V Skorokhodov, Maxim M Gavrik, Nona N Mkrtchan, Marek Majdan, Peter Valkovic, Daria Rabarova, Suzanne Barker-Collo, Kelly Jones, Valery L Feigin

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury

    A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury by Pavel I. Pilipenko, Anna A. Ivanova, Yulia V. Kotsiubinskaya, Vera N. Grigoryeva, Alexey Y. Khrulev, Anatoly V. Skorokhodov, Maxim M. Gavrik, Nona N. Mkrtchan, Marek Majdan, Peter Valkovic, Daria Rabarova, Suzanne Barker-Collo, Kelly Jones, Valery L. Feigin

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: